The Real Impact for Healthcare and Biotechnology of the Supreme Court's Decision in Myriad Genetics

more+
less-

 

Topics:  ACLU, AMP v Myriad, Bio, DNA, Genetic Materials, Health, Myriad, Patent-Eligible Subject Matter, Patents, SCOTUS, USPTO

Published In: Intellectual Property Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Bradley Arant Boult Cummings LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »